PHARMA INTEGRATES 2103 London

November 26th-27th

Prof Trevor M Jones CBE. PhD DSc. FRSC. FRSM. Hon FRCP. FBPharmacolS. FFPM.FKC

…we simply have to do better !!The Imperatives for Success

•  Connectivity •  Partnerships •  Strategic Alliances •  Convergence (Technologies)

Convergence    

 Technologies: •  biomedicine, engineering, materials science,

computing, robotics, telecommunications and web services

Cross-sector: •  diagnostics, therapeutics, devices, mobile

(m)health, social media, new data mining services

Integration/Partnerships Out sourcing / “Off-shoring”

•  Discovery support •  Clinical Development •  Data Handling •  Regulatory •  Pharmacovigilance •  Manufacture •  IT •  Sales •  Travel/Meetings/Events •  ………….etc

Connectivity Partnership Strategic Alliances

   

     Change is not a choice !!

Partnerships

“If you want to travel fast… go alone If you want to travel far … go together” Anon:African proverb

•  Pfizer Splits Up Operations Ahead of Possible Breakup

•  More than splitting pills: Health care giant Abbott Laboratories ready to spin off AbbVie

•  New Novartis Chairman Initiates Strategic

Review.

   •  AstraZeneca to axe 1,600 jobs in overhaul of drug R&D

•  Teva to reduce workforce by 5000

•  Merck to cut 8500 MORE jobs by 2015 (in addition to the 7500 jobs cut from 2011 to 2012

•  Valeant Pharmaceuticals International Inc said it would cut 10 to 15 percent jobs after buying contact lens maker Bausch & Lomb. Bausch and Lomb employs about 11,000 people worldwide

Novartis to cut more than 440 jobs in Britain

Shire restructuring will lead to loss

of 180 jobs in UK

October 2013

   

Eighteen GSK China staff held as whistleblower allegations emerge China Investigates Sanofi on Bribery Accusations Novartis faces Chinese bribery allegations AUGUST 16, 2013

   

Main Challenges for the industry ? Scientific • MANY new (unvalidated) targets .Increasingly different (and difficult) product types (Bio/nano/stratified RxDx) • New R&D Models… SME/BigPharma alliances … “learn”& “confirm” Regulatory • Continuing regulatory burden and bureaucracy ….. not just “Q.S.E”………… but, importantly, also “HTA” needs Business • New Markets ...particularly BRIC + • Company restructuring ..M&A ………………..and “cuts” Economic • Continuing “gloomy” Economic Climate

New “Biologicals” Cell Therapy Permanent Replacement Tissue Engineering Transient Cell Therapy Immunomodulation cell therapy Cosmoses / bioaesthetics Delivery vehicles Cell cancer vaccines Xenografts Regenerative Medicine Regenerative Compounds. Regenerative Scaffolds

……….and new Drug Delivery Systems

New “Biologicals” Cell Therapy Permanent Replacement Tissue Engineering Transient Cell Therapy Immunomodulation cell therapy Cosmoses / bioaesthetics Delivery vehicles Cell cancer vaccines Xenografts Regenerative Medicine Regenerative Compounds. Regenerative Scaffolds

……….and new Drug Delivery Systems

…so much more to come !!! Many “new” approaches to therapy

…are you prepared???

   

The imperative to change the Strategic Agenda

•  Change Focus

•  Narrow R&D

•  Rethink “S&M”

•  Increase Flexibility

•  Growth areas ..speciality, emerging markets, generics

•  Fewer areas ,more external ,new R&D models

•  Reduce sales force, new techniques, shift customer focus

•  Reduce fixed infrastructure •  Outsource •  “Smart” Procurement

Re-engineering